Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1113-1126

  Kubera, Marta ^a   Grygier, Beata ^a   Arteta, Beatriz ^b   Urbańska, Krystyna ^c   Basta Kaim, Agnieszka ^a   Budziszewska, Bogusława ^a   Leśkiewicz, Monika ^a   Kołaczkowska, Elzbieta ^c   Maes, Michael ^d   Szczepanik, Marian ^e   Majewska, Monika ^e   Lasoń, Władysław ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d Clinical Research Center for Mental Health of Antwerp   (Belgium)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Desipramine; Fluoxetine; Melanoma; Metastasis

Indexed keywords

CYTOKINE; DESIPRAMINE; FLUOXETINE; GELATINASE B; METALLOPROTEINASE; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VASCULOTROPIN;

AGE; AGED; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CANCER MORTALITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME BLOOD LEVEL; JUVENILE ANIMAL; MALE; MELANOMA B16; MELANOMA B16F10; METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PROTEIN BLOOD LEVEL; SPLEEN CELL; TUMOR CELL; TUMOR GROWTH;

EID: 76049097071     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70174-4     Document Type: Article

References (23)

1. Abdul M, Logothethetis CJ, Hoosein NM: Growt-hinhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol, 1995, 154, 247-250.
2. Ahmed OI, Adel AM, Diab DR, Gobran NS: Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol, 2006, 13, 61-68.
3. Anichini A, Vegetti C, Mortarini R: The paradox of T-cell-mediated immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother, 2004, 53, 855-864.
4. Bendele RA, Adams ER, Hoffman WP Gries CL, Morton DM: Carcinogenicity studies of fluoxetine in rats and mice. Cancer Res, 1992, 52, 6931-6935.
5. Ben-Eliyahu S, Page GG: In vivo assessment of natural killer cell activity in rats. Prog Neuroendocrinimmuol, 1992, 5, 199-214.
6. Bhuvaneswari R, Yuen GY, Chee SK, Olivo M: Hypericin-mediated photodynamic therapy in combination with avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. Phytochem Photobiol Sci, 2007, 6, 1275-1283.
7. Brandes LJ, Arron RJ, Bogdonavic RP Tong J, Zaborniak CL, Hogg GR, Warrington RC et al.: Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res, 1992, 52, 3796-3800.
8. Brandes LJ, Cheang M: Letter regarding "Response to antidepressants and cancer: cause for concern?". J Clin Psychopharmacol, 1995, 15, 84-85.
9. Cha HJ, Jeong MJ, Kleinman HK: Role of thymosin β4 in tumor metastasis and angiogenesis. J Natl Cancer Inst, 2003, 95, 1674-1680.
10. Chlebda E, Merwid-La̧d A, Szumny D, Trocha M, Fereniec- Gołȩbiewska L, Gebarowska E, Kowalski P, Szela̧g A: Antitumor effect of macrolides - erythromycin and roxithromycin in B16 melanoma-transplanted mice. Pharmacol Rep, 2007, 59, Suppl, 269-274.
11. Coopre AM, Khader SA: IL-12p40: an inherently agonistic cytokine, Trends Immunol, 2007, 28, 33-38.
12. Donin N, Sinai J, Michowitz M, Hiss J, Nordenberg J, Leibovici J: Role of immune response as determinant of tumor progression in function of host age in the B16 melanoma. Mech Ageing Dev, 1995, 80, 121-137.
13. Donin N, Sinai J, Staroselsky A, Mahlin T, Nordenberg J, Leibovici J: Comparison of growth rate of two B16 melanomas differing in metastatic potential in young versus middle-aged mice. Cancer Invest, 1997, 15, 416-421.
14. Franco S, Segura I, Riese HH, Blasco MA: Decreased B16F10 melanoma growth and impaired vascularization in telomerase-deficient mice with critically short telomeres. Cancer Research, 2002, 62, 552-559.
15. Frick LR, Palumbo ML, Zappia MP, Brocco MA, Cremaschi GA, Genaro AM: Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T-cell response by serotonin-dependent and independent mechanisms. Biochem Pharmacol, 2008, 75, 1817-1826.
16. Guruvayoorappan C, Kuttan G: Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, nm23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacol Immunotoxicol, 2008, 30, 711-727.
17. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ: Matrix metalloproteinases in human melanoma. J Invest Dermatol, 2000, 115, 337-344.
18. Iishi H, Tatsuta M, Baba M, Taniguchi H: Enhancement by the tricyclic antideprssant, desipramine, of experimental carcinogenesis in rat colon induced by azoxymethane. Carcinogenesis, 1993, 1837-1840.
19. Kaczmarek P, Pokoca L, Niemirowicz J, Majewska E, Baj Z: Effect of luteinizing hormone-releasing hormone (LHRH) analogue treatment on a cytokine profile in prostate cancer patients. Pharmacol Rep, 2008, 60, 399-403.
20. h1 cells pro-inflammatory or anti-inflammatory? The ratio of IL-10 to IFN-γ or IL-2 determines their function. Int Immunol, 1995, 7, 1287-1294.
21. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES: The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol, 2004, 50, 87-100.
22. Kołaczkowska E, Chadzinska M, Ścislowska-Czarnecka A, Płytycz B, Opdenakker G, Arnold B: Gelatinase B/matrix metalloproteinase-9 contributes to cellular infiltration in a murine model of zymosan peritonitis. Immunobiology, 2006, 211, 137-148.
23. Kubera M, Symbirtsev A, Basta-Kaim A, Borycz J, Roman A, Papp M, Claesson M: Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol, 1996, 48, 503-506.